<SEC-DOCUMENT>0001140361-21-021927.txt : 20210622
<SEC-HEADER>0001140361-21-021927.hdr.sgml : 20210622
<ACCEPTANCE-DATETIME>20210622180020
ACCESSION NUMBER:		0001140361-21-021927
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210621
FILED AS OF DATE:		20210622
DATE AS OF CHANGE:		20210622

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Gurrola Sandra M
		CENTRAL INDEX KEY:			0001618457

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		211036532

	MAIL ADDRESS:	
		STREET 1:		2231 RUTHERFORD ROAD
		STREET 2:		SUITE 200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-06-21</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000748592</issuerCik>
        <issuerName>Brooklyn ImmunoTherapeutics, Inc.</issuerName>
        <issuerTradingSymbol>BTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001618457</rptOwnerCik>
            <rptOwnerName>Gurrola Sandra M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BROOKLYN IMMUNOTHERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>140 58TH STREET, BUILDING A, SUITE 2100</rptOwnerStreet2>
            <rptOwnerCity>BROOKLYN</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>11220</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>Vice President of Finance</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8203</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <remarks>Ms. Gurrola previously served as Senior Vice President of Finance for Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) (the &quot;Company&quot;). As reported on an exit Form 4 filed with the Securities and Exchange Commission on March 26, 2021, Ms. Gurrola ceased to be a Section 16 Reporting Officer of the Company effective as of March 25, 2021. Effective as of June 21, 2021, Ms. Gurrola was appointed Vice President of Finance of the Company and thereby again became a Section 16 Reporting Officer of the Company. This Form 3 presents a current listing of all holdings of Company securities as of the effective time of Ms. Gurrola's appointment as Vice President of Finance of the Company.

Exhibit List: Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Mark L. Johnson, Attorney-in-Fact for Sandra M. Gurrola</signatureName>
        <signatureDate>2021-06-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>brhc10026126_ex24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 24</font><br>
  </div>
  <div> <br>
  </div>
  <div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div style="text-align: center; font-style: italic;">(For Executing Forms ID, 3, 4 and 5 for Filing with the Securities and Exchange Commission)</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Know all by these present, that the undersigned hereby constitutes and appoints each of Mark L. Johnson and Bella Zaslavsky of K&amp;L Gates LLP, severally with full power of substitution, as the undersigned&#8217;s true and
      lawful attorneys&#8209;in&#8209;fact to:</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z37c5d8d60fd74c619607a1d3ff18dc68">

        <tr>
          <td style="width: 18pt; vertical-align: top;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>prepare, execute in the undersigned&#8217;s name and on the undersigned&#8217;s behalf, and submit to the Securities and Exchange Commission (the &#8220;<font style="font-style: italic;">SEC</font>&#8221;) from time to time Forms 3, 4 and 5 (including amendments
              thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-style: italic;">Exchange Act</font>&#8221;), and the rules and regulations
              thereunder in the undersigned&#8217;s capacity as an officer of Brooklyn ImmunoTherapeutics, Inc. (the &#8220;<font style="font-style: italic;">Company</font>&#8221;);</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd6f750368d4549e2a4a7cbbb66d17282">

        <tr>
          <td style="width: 18pt; vertical-align: top;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and
              file such forms with the SEC and any stock exchange, self-regulatory association or similar authority; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z52eb5cf033fb4df4a033f2909f0cab5c">

        <tr>
          <td style="width: 18pt; vertical-align: top;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney&#8209;in&#8209;fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that
              the documents executed by either attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney&#8209;in&#8209;fact may approve in the attorney-in-fact&#8217;s
              discretion.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;">The undersigned hereby grants to each such attorney&#8209;in&#8209;fact, severally, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of
      any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that either such
      attorney&#8209;in&#8209;fact, or such attorney&#8209;in&#8209;fact&#8217;s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that, in serving in such capacity
      at the request of the undersigned, neither of the foregoing attorneys-in-fact, or their substitutes, is assuming (nor is the Company assuming) any of the undersigned&#8217;s responsibilities to comply with Section 16 of the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the time as of which the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned&#8217;s
      holdings of and transactions in securities issued by the Company, (b) revocation of this Power of Attorney by the undersigned in a signed writing delivered to the Company and the foregoing attorneys&#8209;in&#8209;fact and (c) with respect to either
      attorney-in-fact, the time as of which such attorney-in-fact is no longer affiliated with K&amp;L Gates LLP.</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-size: 11pt;"><font style="font-size: 10pt; font-variant: small-caps;">In Witness Whereof</font><font style="font-size: 10pt;">, the undersigned has caused this Power of Attorney to be executed as of the date
        written below.</font></div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zf4d38260af8a4f608c339ee433373aaa">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>Date: June 22, 2021</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Sandra Gurrola</div>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <div>Sandra Gurrola</div>
          </td>
          <td style="vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
